0

Lactulose

INQUIRY Add to cart
For Research Use Only | Not For Clinical Use
CATAP4618182-A
CAS4618-18-2
Structure
MDL NumberMFCD00151469
Molecular Weight342.30
EC Number225-027-7
InChI KeyJCQLYHFGKNRPGE-WJONTELPSA-N; traceable to PhEur L0130000; traceable to USP 1356803
REAXYS Number93773
DescriptionPharmaceutical Secondary Standard; Certified Reference Material
Gradecertified reference material; pharmaceutical secondary standard
Size1G
1

A Randomized, Double-Blind, Controlled Trial Comparing Rifaximin Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy

Barjesh Chander Sharma, Praveen Sharma, Manish Kumar Lunia, Siddharth Srivastava, Rohit Goyal, S K Sarin

Am J Gastroenterol. 2013 Sep;108(9):1458-63.

PMID: 23877348

1

Combination of Rifaximin and Lactulose Improves Clinical Efficacy and Mortality in Patients With Hepatic Encephalopathy

Zhida Wang, Pei Chu, Wenjin Wang

Drug Des Devel Ther. 2018 Dec 17;13:1-11.

PMID: 30587923

1

Lactulose Versus Polyethylene Glycol for Chronic Constipation

Heather Lee-Robichaud, Kathryn Thomas, Jenna Morgan, Richard L Nelson

Cochrane Database Syst Rev. 2010 Jul 7;(7):CD007570.

PMID: 20614462

1

Lactulose: Patient- And Dose-Dependent Prebiotic Properties in Humans

Jakub Ruszkowski, Jacek M Witkowski

Anaerobe. 2019 Oct;59:100-106.

PMID: 31176002

1

Long-term Management of Hepatic Encephalopathy With Lactulose and/or Rifaximin: A Review of the Evidence

Mark Hudson, Marcus Schuchmann

Eur J Gastroenterol Hepatol. 2019 Apr;31(4):434-450.

PMID: 30444745

  • Verification code
Contact Us

Send Us a Request

What is your specific need? We will do everything we can to meet your expectations.
Online Inquiry

Inquiry

For any inquiry, question or recommendation, please call: or fill out the following form.

  • Verification code

Head Office

  • Tel:
  • Email:

Follow us on

qrcode